2′,2′-Difluorodeoxyuridine
Based on 1 Customer Validation
2’,2’-Difluorodeoxyuridine (dFdU) is the main metabolite of Gemcitabine (HY-17026). 2’,2’-Difluorodeoxyuridine causes a concentration- and schedule- dependent radiosensitising effect in vitro. 2’,2’-Difluorodeoxyuridine arrests cell cycle at the early S phase and induces apoptosis in cancer cells.
For research use only. We do not sell to patients.
- Purity : 99.82%
- CAS No.: 114248-23-6
- Formula: C9H10F2N2O5
- Molecular Weight:264.18
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
In Vitro
2’,2’-Difluorodeoxyuridine (10-100 μM, 24 h before radiation immediately or 8 or 24 h later) shows concentration-dependent and schedule-dependent radiosensitising effect in both ECV304 and H292 cells[1].
2’,2’-Difluorodeoxyuridine (100-250 μM, 24 h) increases apoptosis in both ECV304 and H292 cells[1].
2’,2’-Difluorodeoxyuridine (10-250 μM, 24 h) can arrest cell cycle at the early S phase in both ECV304 and H292 cells[1].
2’,2’-Difluorodeoxyuridine (48 h-14 d) is cytotoxic to HepG2 and A549 cancer cells (IC50s = 3.13 and 3.92 μM, respectively)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:ECV304 (mutant p53, human bladder cancer cell line), H292 (wild-type p53, a human mucoepidermoid lung cancer cell line)
-
Concentration:10, 20, 50 μM (ECV304), 25, 50, 100 μM (H292)
-
Incubation Time:incubated for 24 h and irradiated immediately or 8 or 24 h later
-
Result:Showed clear concentration-dependent radiosensitising effect.
Increased dose enhancement factor (DEF) with an increasing concentration.
Showed clear schedule-dependent radiosensitising effect.
Radiosensitising effect decreased with a longer interval between chemotherapy and radiation; the DEF decreased with an interval of 8 or 24 h.
-
Cell Line:ECV304 (mutant p53, human bladder cancer cell line), H292 (wild-type p53, a human mucoepidermoid lung cancer cell line)
-
Concentration:100 μM (ECV304), 250 μM (H292)
-
Incubation Time:24 h
-
Result:The amount of early apoptotic cells increased.
The induction of apoptosis under radiosensitising conditions seemed cell line dependent.
-
Cell Line:ECV304 (mutant p53, human bladder cancer cell line), H292 (wild-type p53, a human mucoepidermoid lung cancer cell line)
-
Concentration:10, 20, 50, 100 μM (ECV304), 10, 50, 100, 250 μM (H292)
-
Incubation Time:24 h
-
Result:Caused a block of cells in the S phase of the cell cycle in both ECV304 and H292 cells, and was concentration dependent.
The greatest DEFs were observed when most cells were blocked in the early S phase of the cell cycle.
-
Cell Line:ECV304 (mutant p53, human bladder cancer cell line), H292 (wild-type p53, a human mucoepidermoid lung cancer cell line)
-
Concentration:100 μM (ECV304), 250 μM (H292)
-
Incubation Time:24 h
-
Result:Increased cleaved caspase 3, indicating the induction of apoptosis.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 114248-23-6
-
Appearance Solid
-
Molecular Weight 264.18
-
Formula C9H10F2N2O5
-
Color White to off-white
-
SMILES
O=C(N1)N([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)C=CC1=O
-
Synonyms
dFdU; 2',2'-Difluoro-2'-deoxyuridine
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 125 mg/mL (473.16 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 100 mg/mL (378.53 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (18.93 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (18.93 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Protocols
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Pauwels B, et al. The radiosensitising effect of difluorodeoxyuridine, a metabolite of gemcitabine, in vitro. Cancer Chemother Pharmacol. 2006 Aug;58(2):219-28. [Content Brief]
[2]. Veltkamp SA, et al. New insights into the pharmacology and cytotoxicity of gemcitabine and 2',2'-difluorodeoxyuridine. Mol Cancer Ther. 2008 Aug;7(8):2415-25. [Content Brief]
[3]. Veltkamp SA, et al. Extensive metabolism and hepatic accumulation of gemcitabine after multiple oral and intravenous administration in mice. Drug Metab Dispos. 2008 Aug;36(8):1606-15. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 3.7853 mL | 18.9265 mL | 37.8530 mL | 94.6325 mL |
| 5 mM | 0.7571 mL | 3.7853 mL | 7.5706 mL | 18.9265 mL | |
| 10 mM | 0.3785 mL | 1.8926 mL | 3.7853 mL | 9.4632 mL | |
| 15 mM | 0.2524 mL | 1.2618 mL | 2.5235 mL | 6.3088 mL | |
| 20 mM | 0.1893 mL | 0.9463 mL | 1.8926 mL | 4.7316 mL | |
| 25 mM | 0.1514 mL | 0.7571 mL | 1.5141 mL | 3.7853 mL | |
| 30 mM | 0.1262 mL | 0.6309 mL | 1.2618 mL | 3.1544 mL | |
| 40 mM | 0.0946 mL | 0.4732 mL | 0.9463 mL | 2.3658 mL | |
| 50 mM | 0.0757 mL | 0.3785 mL | 0.7571 mL | 1.8926 mL | |
| 60 mM | 0.0631 mL | 0.3154 mL | 0.6309 mL | 1.5772 mL | |
| 80 mM | 0.0473 mL | 0.2366 mL | 0.4732 mL | 1.1829 mL | |
| 100 mM | 0.0379 mL | 0.1893 mL | 0.3785 mL | 0.9463 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.